New Enterprise Associates

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Ravel Law, Inc. operates a legal analytics platform that provides tools for lawyers to find, contextualize, and interpret legal information, transforming data into actionable insights. Founded in 2012 and based in San Francisco, California, the company offers a suite of analytical research tools, including court, judge, and case analytics, along with interactive visualizations. These resources are designed to assist attorneys, law students, and legal professionals in analyzing and understanding legal data effectively. By providing data-driven insights, Ravel Law enhances the way legal practitioners prepare for litigation and navigate complex legal landscapes. The company operates as a subsidiary of LexisNexis Legal & Professional Inc., having spun out from Stanford University’s Law School, Computer Science Department, and d.school.

Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.

Ravel Law, Inc. operates a legal analytics platform that provides tools for lawyers to find, contextualize, and interpret legal information, transforming data into actionable insights. Founded in 2012 and based in San Francisco, California, the company offers a suite of analytical research tools, including court, judge, and case analytics, along with interactive visualizations. These resources are designed to assist attorneys, law students, and legal professionals in analyzing and understanding legal data effectively. By providing data-driven insights, Ravel Law enhances the way legal practitioners prepare for litigation and navigate complex legal landscapes. The company operates as a subsidiary of LexisNexis Legal & Professional Inc., having spun out from Stanford University’s Law School, Computer Science Department, and d.school.

Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.

Ravel Law, Inc. operates a legal analytics platform that provides tools for lawyers to find, contextualize, and interpret legal information, transforming data into actionable insights. Founded in 2012 and based in San Francisco, California, the company offers a suite of analytical research tools, including court, judge, and case analytics, along with interactive visualizations. These resources are designed to assist attorneys, law students, and legal professionals in analyzing and understanding legal data effectively. By providing data-driven insights, Ravel Law enhances the way legal practitioners prepare for litigation and navigate complex legal landscapes. The company operates as a subsidiary of LexisNexis Legal & Professional Inc., having spun out from Stanford University’s Law School, Computer Science Department, and d.school.

Prosensa, also known as Ribpharm Inc, is a biotech company specializing in the discovery, development, and commercialization of RNA-based therapeutics. The company is particularly focused on addressing genetic disorders, with an emphasis on neuromuscular conditions, as well as anti-infectives and oncology. Prosensa aims to leverage its strong intellectual property position to capitalize on emerging market opportunities in the healthcare sector. To optimize its operations, the company adopts a focused business model by outsourcing most activities to specialized organizations. Through its innovative approach, Prosensa seeks to bring novel and commercially viable therapeutic products to market.

Aryx Therapeutics is a biopharmaceutical company that specializes in the development of innovative oral therapies aimed at chronic diseases. The company leverages its expertise in retrometabolic drug design to create product candidates that address and eliminate safety concerns associated with existing, commercially successful medications. By focusing on improving the safety profiles of these therapies, Aryx Therapeutics seeks to enhance patient outcomes and provide better treatment options in the pharmaceutical market. The company's commitment to advancing drug safety is supported by a strong portfolio of intellectual property.

TiVo Corporation, headquartered in San Jose, California, specializes in media and entertainment products for the consumer entertainment industry worldwide. It operates in two main segments: Product and Intellectual Property Licensing. The Product segment offers platform solutions, including User Experience Solutions, TiVo Service Platform, and middleware solutions like CubiTV and TiVo Lite, serving 25 million pay TV and consumer households as of 2019. It also provides software and services such as metadata, personalized content discovery, and advanced media and advertising services. The Intellectual Property Licensing segment licenses its patent portfolio to various entities, including pay-television providers, mobile device manufacturers, and over-the-top video providers. TiVo, originally known as Rovi Corporation, changed its name in 2016 and operates as a subsidiary of Xperi Corporation since 2020.

QuickLogic Corporation is a semiconductor company that specializes in developing customizable semiconductor platforms and intellectual property solutions for various applications, including smartphones, wearables, tablets, and Internet-of-Things devices. The company offers a range of products such as ultra-low power field programmable gate arrays (FPGAs), embedded FPGA intellectual property, System on Chip (SoC) solutions, and an analytics toolkit designed for machine learning and sensor algorithm development. QuickLogic's solutions are tailored for always-on voice and sensor processing, enhancing user experiences in mobile and portable electronics. Additionally, the company provides licensing for its FPGA technology to other semiconductor firms. Founded in 1988 and headquartered in San Jose, California, QuickLogic markets its products to original equipment manufacturers and original design manufacturers through a network of sales managers and distributors across North America, Europe, and Asia.